周俊梅;杨幸文;白永杰;

• 1:郑州市第二人民医院

摘要(Abstract)：

目的探讨卡巴拉汀联合左旋多巴治疗中晚期帕金森病的认知功能障碍以及对血清表皮生长因子(EGF)和淀粉样蛋白(Aβ_(1-42))的影响。方法选取2017-01—2019-07郑州市第二人民医院收治的中晚期帕金森患者140例,将其随机分为对照组和观察组,每组70例。对照组给予左旋多巴治疗,观察组采用卡巴拉汀联合左旋多巴,所有患者均干预3个月。采用MoCA量表、MMSE量表评价认知功能,采用UPDRS量表评估病情,采用CSI量表评估肌张力,并检测患者DAT活性、血清EGF水平与Aβ_(1-42)水平以及药物的不良反应。结果干预前,2组患者MoCA评分、MMSE评分、UPDRS评分、CSI评分、DAT活性、血清EGF水平以及Aβ_(1-42)水平差异无统计学意义(P>0.05);干预后,2组患者的UPDRS评分、CSI评分、血清EGF水平较治疗前均有所下降(P<0.05),观察组下降幅度更加明显(P<0.05);干预后2组MoCA评分、MMSE评分、血清Aβ_(1-42)水平较治疗前均有所增高(P<0.05),观察组患者增高更加明显(P<0.05);干预后2组DAT活性均有所降低(P<0.05),观察组降低幅度小于对照组;2组患者不良反应发生率相比差异无统计学意义(P>0.05)。结论卡巴拉汀联合左旋多巴治疗中晚期帕金森具有良好的治疗效果,安全性高。

关键词(KeyWords)： 帕金森;左旋多巴;卡巴拉汀;EGF;Aβ_(1-42)

Abstract:

Keywords:

基金项目(Foundation): 河南省医学科技攻关计划项目(编号:201702306)

作者(Authors): 周俊梅;杨幸文;白永杰;

参考文献(References)：

• [1] REICH S G,SAVITT J M.Parkinson's Disease[J].Med Clin North Am,2019,103(2):337-350.
• [2] CABREIRA V,MASSANO J.Doen?a de Parkinson:Revis?o Clínica e Atualiza??o[J].Acta Médica Portuguesa,2019,32(10):3321-3327.
• [4] TORSNEY K M,FORSYTH D.Respiratory dysfunction in Parkinson’s disease[J].J R Coll Physicians Edinb,2017,47(1):35-39.
• [5] GUL A.YOUSAF J.Effect of levodopa on frontal-subcortical and posterior cortical functioning in patients with Parkinson’s disease[J].Singapore Med J,2019,60(8):414-417.
• [6] CABREIRA V,MASSANO J.Doen?a de Parkinson:Revis?o Clínica e Atualiza??o[J].Acta Med Port,2019,32(10):338-342.
• [7] MULLER T,MOHT J D.Efficacy of carbidopa-levodopa extended-release capsules (IPX066) in the treatment of Parkinson Disease[J].Expert Opin Pharmacother,2018,19(18):2063-2071.
• [8] CHANG C C,PENG G S,LAI T J.A 48-Week,Multicenter,Open-Label,Observational Study Evaluating Oral Rivastigmine in Patients with Mild-to-Moderate Alzheimer’s Disease in Taiwan[J].Adv Ther,2019,36(6):1455-1464.
• [7] GAO G,Du S,YANG Y.Direct Asymmetric Reductive Amination for the Synthesis of (S)-Rivastigmine[J].Molecules,2018,23(9):986-994.
• [8] VIRACHIT S,Mathews K J,Cottam V.Levels of glial cell line-derived neurotrophic factor are decreased,but fibroblast growth factor 2 and cerebral dopamine neurotrophic factor are increased in the hippocampus in Parkinson's disease[J].Brain Pathol,2019,29(6):813-825.
• [9] LIM NS,SWANGSM C R,CHERNG H R.Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease[J].Ann Clin Transl Neurol,2016,3(5):346-355.
• [10] DELGADO-ALVARADO M,Gago B,Navalpotro-Gomez I.Biomarkers for dementia and mild cognitive impairment in Parkinson's disease[J].Mov Disord,2016,31(6):861-881.
• [11] 肖一峰,吴婧.帕金森病嗅觉障碍研究进展[J].中国实用神经疾病杂志,2020,23(16):1466-1472.
• [12] O'DRISOLL C.SHAIKH M.Cross-Cultural Applicability of the Montreal Cognitive Assessment (MoCA):A Systematic Review[J].J Alzheimers Dis,2017,58(3):789-801.
• [13] BAHAT G,ERDAGAN T,KARAN M A.At which Hoehn&Yahr stage of Parkinson's disease should the patients be screened for dysphagia?[J].Clin Nutr,2020,39(1):980-988.
• [14] YOELIN A B,SAUNDERS N W.Score Disparity Between the MMSE and the SLUMS[J].Am J Alzheimer's Dis Other Demen,2017,32(5):282-288.
• [15] BROOKS C,EDEN G,CHANG A.Quantification of discrete behavioral components of the MDS-UPDRS[J].J Clin Neurosci,2019,61(18):174-179.
• [16] MILINIS K,TENNANT A,MILLS R J.Development and validation of Spasticity Index-Amyotrophic Lateral Sclerosis[J].Acta Neurol Scand,2018,138(1):47-54.
• [17] CERRI S,BLANDINI F.Role of Autophagy in Parkinson's Disease[J].Curr Med Chem,2019,26(20):3702-3718.
• [18] MONACO M R L,PETRACCA M,Weintraub D.Prevalence of Impulsive-Compulsive Symptoms in Elderly Parkinson’s Disease Patients[J].J Clin Psychiatry,2018,79(3):1132-1136.
• [19] PATHAK-GANDHI N,VAIDYA A D B.Management of Parkinson's disease in Ayurveda:Medicinal plants and adjuvant measures[J].J Ethnopharmacol,2017,19(3):46-51.
• [20] ALVAREZ F J.Parkinson’s disease,antiparkinson medicines,and driving[J].Expert Rev Neurother,2016,16(9):1023-1032.
• [21] MAMIKONYAN E,XIE S X.Rivastigmine for mild cognitive impairment in Parkinson disease:a placebo-controlled study[J].Mov Disord,2015,30(7):912-918.
• [22] FOX S H,LIM S Y.International Parkinson and movement disorder society evidence-based medicine review:Update on treatments for the motor symptoms of Parkinson's disease[J].Mov Disord,2018,33(8):1248-1266.
• [23] JIANG L,ZHANG H,WANG C.Serum level of brain-derived neurotrophic factor in Parkinson's disease:a meta-analysis[J].Prog Neuropsychopharmacol Biol Psychiatry,2019,88:168-174.
• [24] JALILZAD M,JAFARI A,BABAEI P.Neuregulin1β improves both spatial and associative learning and memory in Alzheimer model of rats possibly through signaling pathways other than Erk1/2[J].Neuropeptides,2019,78:101963.DOI:10.1016/j.npep.2019.101963.
• [25] LOEFFLER D A,AASLY J O,LEWITT P A,et al.What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson’s Disease Patients and Healthy Subjects with Parkinson’s-Associated LRRK2 Mutations?[J].J Parkinsons Dis,2019,9(3):467-488.DOI:10.3233/JPD-191630.
• [26] MURAKAMI H,TOKUDA T,EL-AGNAF O M A,et al.Correlated levels of cerebrospinal fluid pathogenic proteins in drug-na?ve Parkinson’s disease[J].BMC Neurol,2019,19(1):113.DOI:10.1186/s12883-019-1346-y.
• [27] BA F,ZHOU Y,ZHOU J,et al.Repetitive transcranial magnetic stimulation protects mice against 6-OHDA-induced Parkinson’s disease symptoms by regulating brain amyloid β1-42 level[J].Mol Cell Biochem,2019,458(1/2):71-78.DOI:10.1007/s11010-019-03531-w.
• [28] FIORENZATO E,BIUNDO R,CECCHIN D,et al.Brain Amyloid Contribution to Cognitive Dysfunction in Early-Stage Parkinson’s Disease:The PPMI Dataset[J].J Alzheimers Dis,2018,66(1):229-237.DOI:10.3233/JAD-180390.
• [29] ALLALI G,KERN I,LAIDET M,et al.Parkinsonism is a Phenotypical Signature of Amyloidopathy in Patients with Gait Disorders[J].J Alzheimers Dis,2018,63(4):1373-1381.DOI:10.3233/JAD-171055.
• [30] SIMUNI T,CASPELL-GARCIA C,COFFEY C S,et al.Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease:the PPMI cohort[J].J Neurol Neurosurg Psychiatry,2018,89(1):78-88.DOI:10.1136/jnnp-2017-316213.
• [31] RIVERO-RíOS P,ROMO-LOZANO M,MADERO-PéREZ J,et al.The G2019S variant of leucine-rich repeat kinase 2 (LRRK2) alters endolysosomal trafficking by impairing the function of the GTPase RAB8A[J].J Biol Chem,2019,294(13):4738-4758.DOI:10.1074/jbc.RA118.005008.
• [32] NAKASHIMA Y,MIYAGI-SHIOHIRA C,NOGUCHI H,et al.The Healing Effect of Human Milk Fat Globule-EGF Factor 8 Protein (MFG-E8) in A Rat Model of Parkinson’s Disease[J].Brain Sci,2018,8(9):167.DOI:10.3390/brainsci8090167.
• [33] XIAO L Y,WANG X R,YANG Y,et al.Applications of Acupuncture Therapy in Modulating Plasticity of Central Nervous System[J].Neuromodulation,2018,21(8):762-776.DOI:10.1111/ner.12724.
• [34] PAL R,TIWARI P C,NATH R,et al.Role of neuroinflammation and latent transcription factors in pathogenesis of Parkinson’s disease[J].Neurol Res,2016,38(12):1111-1122.DOI:10.1080/01616412.2016.1249997.
• [35] KIM V,CORNWELL W D,OROS M,et al.Plasma Chemokine signature correlates with lung goblet cell hyperplasia in smokers with and without chronic obstructive pulmonary disease[J].BMC Pulm Med,2015,15:111.DOI:10.1186/s12890-015-0103-2.
• [36] TAKAHASHI-NIKI K,KATO-OSE I,MURATA H,et al.Epidermal Growth Factor-dependent Activation of the Extracellular Signal-regulated Kinase Pathway by DJ-1 Protein through Its Direct Binding to c-Raf Protein[J].J Biol Chem,2015,290(29):17838-17847.DOI:10.1074/jbc.M115.666271.
• [37] JIANG Q W,WANG C,ZHOU Y,et al.Plasma epidermal growth factor decreased in the early stage of Parkinson’s disease[J].Aging Dis,2015,6(3):168-173.DOI:10.14336/AD.2014.0925.
• [38] GARRETT S L,MCDANIEL D,OBIDEEN M,et al.Racial Disparity in Cerebrospinal Fluid Amyloid and Tau Biomarkers and Associated Cutoffs for Mild Cognitive Impairment[J].JAMA Netw Open,2019,2(12):e1917363.DOI:10.1001/jamanetworkopen.2019.17363.
• [39] WU H E,TEIXEIRA A L,BARROSO L.Epidermal growth factor and fibroblast growth factor-2 circulating levels in elderly with major depressive disorder[J].Psychiatry Res,2019,272:141-143.
• [40] IKEDA K,EBINA J,KAWABE K.Dopamine Transporter Imaging in Parkinson Disease:Progressive Changes and Therapeutic Modification after Anti-parkinsonian Medications[J].Intern Med,2019,58(12):1665-1672.